SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS)
IONS 81.94-0.3%Jan 28 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: sds who wrote (1922)4/10/1998 12:46:00 AM
From: Miljenko Zuanic  Read Replies (1) of 4676
 
sds:

I agree with ewolf that Fomivirsen can be reviewed by FDA in relative short time. From three NDA review categories: regular, expedited and fast track review, fomivirsen should feet somewhere between regular and expedited.

It was true that FDA was on Isis back for past few years, so they do know well not only Fomivirsen,, but 2302,...Also, depend how busy is antiviral dept. at FDA. Add that Isis submitted large part of NDA file electronically (maybe first one?), review should not take that long. But, who knows FDA and their status?

Anyway, in next 12 months real story (or more accurate) about CMV retinitis will be available and with this Fomivirsen near term revenue potential.

mz
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News